ecog-e1910 study: clinical benefit of early blinatumomab incorporation in all
Published 9 months ago • 167 plays • Length 1:03Download video MP4
Download video MP3
Similar videos
-
3:54
a case study from the ecog-e1910 trial: early blinatumomab treatment in all
-
1:47
the role of blinatumomab in all
-
3:21
ash 2022 lba: results from the ecog-acrin e1910 trial
-
2:23
the value of blinatumomab in all and future therapeutic considerations
-
1:22
final results of allg all08: blinatumomab with reduced intensity chemo in older adults with b-all
-
4:45
day in the life of a doctor: hematology rotation
-
5:54
day in the life - haematology - dr ellen maxwell
-
5:13
what is a haematologist?
-
4:13
real-world outcomes of patients with r/r b-all treated with blinatumomab and inotuzumab ozogamicin
-
1:12
ponatinib and blinatumomab in newly diagnosed ph all: subgroup analysis from phase ii study
-
2:17
choosing between inotuzumab ozogamicin and blinatumomab in patients with r/r all
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
0:47
novel targeted antibodies for r/r b-all
-
2:41
an overview of the latest advances in hematology
-
0:45
difference between quality of life & patient-reported outcomes
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
2:31
ponatinib & blinatumomab for ph all
-
1:25
the management of cll in italy